B35	Prevalence of baseline virological risk factors of increased virological failure to CAB+RPV among ARV-naïve patients	On-demand oral abstract session	Regimen simplification and switch studies
B35	APOBEC editing in HIV DNA proviral vif and pol long-reads issued from virologically-suppressed patients included in the ANRS LAMIDOL trial	On-demand oral abstract session	Regimen simplification and switch studies
B35	Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA)	Oral abstract session with live Q&A	Regimen simplification and switch studies
B35	Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance	E-poster	Regimen simplification and switch studies
B35	Switch to BIC/FTC/TAF in virally suppressed PLWH: efficacy and tolerability	E-poster	Regimen simplification and switch studies
B35	Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/F/TAF) for maintenance of viral suppression in adults with historical virological failure and K65N/R mutation	E-poster	Regimen simplification and switch studies
B35	Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: week 96 results from an international, Phase 3b, open-label trial	E-poster	Regimen simplification and switch studies
B35	Week 72 outcomes and COVID-19 impact from The BRAAVE 2020 study: a randomized switch to B/F/TAF in African American adults living with HIV	E-poster	Regimen simplification and switch studies
B35	Successfully (and safely) enrolling a multi-center HIV antiretroviral clinical trial during the COVID-19 pandemic: lessons learned from Kenya	E-poster	Regimen simplification and switch studies
B35	DTG+3TC in GEMINI-1&-2: HIV-1 replication at <50 c/mL and VL blips through 144 weeks	E-poster	Regimen simplification and switch studies